Previously treated patients with metastatic pancreatic adenocarcinoma were randomly assigned at a ratio of 2:1 to two doses of Cy/GVAX followed by four doses of CRS-207 ( arm A ) or six doses of Cy/GVAX ( arm B ) every 3 weeks .